2 recruiting, 1 active not recruiting, 1 not yet recruiting, 1 unknown. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow EGFR-mutant Non-small Cell Lung Cancer: new trials by email Literature Review of EGFR-mutant Non-small Cell Lung Cancer trials Research Report on EGFR-mutant Non-small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy Third-generation EGFR tyrosine kinase inhibitor, Platinum plus pemetrexed chemotherapy, Pemetrexed maintenance therapy - EGFR-mutant Non-small Cell Lung Cancer, SBRT | Phase 2 | Not yet recruiting | Fudan University | 374 | 2026-10-01 | 2026-09-16 |
| Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer Sacituzumab Tirumotecan and Limertinib - EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 36 | 2026-01-01 | 2026-01-07 |
| A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer VRN110755 - EGFR-Mutant Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Voronoi, Inc | 315 | 2024-03-26 | 2026-07-13 |
| A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC famitinib po, HS-10296 po - EGFR-mutant Non-Small Cell Lung Cancer | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 58 | 2019-04-25 | 2022-07-07 |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC EGF816, trametinib, ribociclib - EGFR-mutant Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 105 | 2018-01-29 | 2026-01-16 |
Carcinoma, Non-Small-Cell Lung (3)
Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Lung Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3)
Gefitinib (1) · Platinum (1) · capmatinib (1) · naporafenib (1) · nazartinib (1) · ribociclib (1) · trametinib (1)
Fudan University (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Voronoi, Inc (1)
Canada (2) · China (2) · Hong Kong (2) · Singapore (2) · Taiwan (2) · Australia (1) · France (1) · Germany (1) · Italy (1) · Malaysia (1) · South Korea (1) · Spain (1) · Thailand (1)
Caicun Zhou, PhD (1) · Hongryul Jung, PhD (1)
2025 (1)